|
Re: HDL Functionality
|
3
|
Resverlogix Corp.
|
May 09, 2019 02:47PM
|
|
Re: HDL Functionality
|
2
|
Resverlogix Corp.
|
May 08, 2019 02:23PM
|
|
Re: And there's the news, 3 month loan extension....
|
4
|
Resverlogix Corp.
|
May 04, 2019 02:14PM
|
|
Re: Classifying/taxonomy mCRPC patients
|
2
|
Zenith Epigenetics
|
May 01, 2019 03:27PM
|
|
Re: Not quite a breakout yet....
|
3
|
Resverlogix Corp.
|
Apr 20, 2019 02:32PM
|
|
Classifying/taxonomy mCRPC patients
|
4
|
Zenith Epigenetics
|
Apr 20, 2019 02:12PM
|
|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
2
|
Resverlogix Corp.
|
Apr 18, 2019 02:55PM
|
|
Value of the accumulated deficit - a question
|
3
|
Resverlogix Corp.
|
Apr 17, 2019 04:39PM
|
|
Re: ZCC relationship to ZEL!
|
4
|
Zenith Epigenetics
|
Apr 13, 2019 01:53PM
|
|
Re: Updated List of BET inhibitors
|
3
|
Zenith Epigenetics
|
Apr 12, 2019 03:02PM
|
|
Re: Epigenetics: an exciting new approach in prostate cancer
|
4
|
Zenith Epigenetics
|
Apr 09, 2019 03:27PM
|
|
Re: RBC unregistered to registered account
|
4
|
Zenith Epigenetics
|
Apr 02, 2019 03:18PM
|
|
Re: RBC unregistered to registered account
|
5
|
Zenith Epigenetics
|
Mar 30, 2019 02:21PM
|
|
Re: No mention of efficacy again...
|
3
|
Resverlogix Corp.
|
Mar 29, 2019 03:12PM
|
|
Re: Goodbye March, Hello April
|
3
|
Resverlogix Corp.
|
Mar 26, 2019 03:23PM
|
|
Re: Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
3
|
Zenith Epigenetics
|
Mar 21, 2019 03:07PM
|
|
Re: Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
4
|
Zenith Epigenetics
|
Mar 20, 2019 04:50PM
|
|
Re: What if
|
3
|
Resverlogix Corp.
|
Mar 06, 2019 03:23PM
|
|
Re: Zacks SCR Resverlogix Report 12/28/18
|
1
|
Resverlogix Corp.
|
Feb 26, 2019 03:59PM
|
|
Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.
|
2
|
Zenith Epigenetics
|
Feb 11, 2019 01:27PM
|
